Skip to main content
. Author manuscript; available in PMC: 2022 Jul 15.
Published in final edited form as: Nat Metab. 2021 Nov 18;3(11):1512–1520. doi: 10.1038/s42255-021-00465-w

Figure 4. MTR supports purine biosynthesis by promoting folate availability.

Figure 4.

Relative abundance of (A) purine biosynthetic intermediates and (B) nucleotides in HCT116 control and MTR knockout cells in media with indicated folate sources. Intensities are normalized to the average of control-1 cells in folic acid (mean ± SD, n = 3). Relative abundance of (C) purine biosynthetic intermediate and (D) nucleotides in control and MTR knockout cells grown in media with 5-methyl-THF, with and without the addition of 1 mM formate (mean ± SD, n = 3). (E) Relative abundance of purine biosynthetic intermediate and nucleotide triphosphates in individual HCT116 control and MTR knockout subcutaneous tumors (normalized to control tumor average). TIC = total ion count. For (B) and (D), P values were determined by a one-way ANOVA comparing control to MTR knockout in the same medium followed by Dunnett’s post hoc analysis.